drugset / Trial / NCT06823167
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NaSequentialOpen-labelTreatment
Summary
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Timeline
- Start
- 2025-02-26
- Primary completion
- 2028-05
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IM-1021 | Other / unclassified | 2 mg/kg | Intravenous |